Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients

KRAS is an independent negative predictor for anti-epidermal growth factor receptor (anti-EGFR) treatment in colorectal cancers (CRCs). However, 30% to 50% of CRC patients are KRAS-positive and do not benefit from anti-EGFR therapy. In this study, we investigated the mutational features and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhouhuan, Kong, Linghong, Wan, Zhiyi, Zhu, Fengwei, Zhong, Mei, Lv, Yali, Zhao, Po, Shi, Huaiyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858340/
https://www.ncbi.nlm.nih.gov/pubmed/31729406
http://dx.doi.org/10.1038/s41598-019-53039-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858340/
https://www.ncbi.nlm.nih.gov/pubmed/31729406
http://dx.doi.org/10.1038/s41598-019-53039-y

Ejemplares similares